Regulatory optimism and strategic partnerships boost investor confidence despite ongoing risks
Shares of Hims & Hers Health (HIMS) surged for a second consecutive day, rising 6% in early Thursday trading as investors reacted positively to potential regulatory changes from the U.S. Food and Drug Administration. The rally builds on a 13% gain from the previous session, following news that the agency will review restrictions on several peptides—substances increasingly central to the company’s growth strategy.
The FDA has scheduled a July meeting to evaluate whether seven peptides should be moved out of Category 2, a classification reserved for substances considered too risky or insufficiently studied for compounding. According to Health Secretary Robert F. Kennedy Jr., these substances will be assessed by the Pharmacy Compounding Advisory Committee, signaling a willingness to reconsider prior limitations based on updated scientific evidence. This shift is viewed as a meaningful step toward restoring regulated access and reducing reliance on unregulated markets.
For Hims & Hers, the regulatory momentum is particularly significant. The company invested in a peptide manufacturing facility in California last year, aiming to expand offerings in areas such as weight loss and muscle recovery. A more favorable FDA stance could unlock new revenue streams and strengthen its position in the telehealth and wellness market.
Despite the recent gains, Hims & Hers stock remains down 23% year-to-date, largely due to regulatory uncertainty surrounding compounded versions of GLP-1 weight-loss drugs. However, a recent collaboration with Novo Nordisk has helped ease some concerns. The partnership provides customers access to FDA-approved treatments while allowing limited distribution of compounded semaglutide.
As regulatory clarity improves, investors appear increasingly optimistic about the company’s long-term outlook.
You might like this article:Tech Stocks Rally as Geopolitical Tensions Ease and AI Headlines Intensify
